Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Sharon A. Vantyghem"'
Autor:
Alison L. Allan, Ann F. Chambers, Michael Keeney, Sharon A. Vantyghem, Alan B. Tuck, Carl O. Postenka, Waleed Al-Katib
Publikováno v:
Clinical & Experimental Metastasis. 22:351-361
Breast cancer often spreads from the primary tumor to regional lymph nodes. Lymph node status provides clinically important information for making treatment decisions. Spread via lymphatics is also important for the biology of breast cancer, as tumor
Autor:
Carl O. Postenka, Sylvia M. Wilson, Ann F. Chambers, Alan B. Tuck, Sharon A. Vantyghem, Waleed Al-Katib
Publikováno v:
Cancer Research. 65:3396-3403
Metastatic spread, not primary tumor burden, is the leading cause of breast cancer deaths. For patient prognosis to improve, new systemic adjuvant therapies that are capable of effectively inhibiting the outgrowth of seeded tumor cells after surgical
Publikováno v:
Journal of Mammary Gland Biology and Neoplasia. 4:415-423
Angiogenesis, the development of new blood vessels, is crucial for the growth of both primary tumors and metastases beyond a minimal size and the vasculature of tumors facilitates their metastatic spread. Inhibition of angiogenesis is thus seen as a
Autor:
Terlika S, Pandit, Wendy, Kennette, Lisa, Mackenzie, Guihua, Zhang, Waleed, Al-Katib, Joseph, Andrews, Sharon A, Vantyghem, D George, Ormond, Alison L, Allan, David I, Rodenhiser, Ann F, Chambers, Alan B, Tuck
Publikováno v:
International journal of oncology. 35(2)
Although lymphatic dissemination is a major route for breast cancer metastasis, there has been little work to determine what factors control the ability of tumor cells to survive, establish and show progressive growth in a lymph node environment. Thi
Autor:
D. George Ormond, Wendy Kennette, Joseph Andrews, David I. Rodenhiser, Alison L. Allan, Lisa Mackenzie, Ann F. Chambers, Alan B. Tuck, Waleed Al-Katib, Guihua Zhang, Terlika S. Pandit, Sharon A. Vantyghem
Publikováno v:
Oncology Publications
Although lymphatic dissemination is a major route for breast cancer metastasis, there has been little work to determine what factors control the ability of tumor cells to survive, establish and show progressive growth in a lymph node environment. Thi
Publikováno v:
Breast disease. 26
Breast cancer remains a leading cause of morbidity and mortality in women, mainly due to the propensity of primary breast tumors to metastasize to regional and distant sites. Metastatic spread after the removal of a primary tumor can be difficult to
Autor:
Ann F. Chambers, Nicole Hodgson, David P. Girvan, Carl O. Postenka, Waleed Al-Katib, Leslie Scott, Alison L. Allan, Rosamma George, Toshimitsu Uede, Larry Stitt, Ron L. Holliday, Mark W. Lee, C. Jay Engel, Sharon A. Vantyghem, Alan B. Tuck
Publikováno v:
The American journal of pathology. 169(1)
Although a primary route of breast cancer metastasis is believed to be via lymphatics, the molecular factors involved are poorly understood. We hypothesized that one such factor may be the integrin-binding protein osteopontin (OPN), and we investigat
Autor:
Michael Keeney, Ian Chin-Yee, Ann F. Chambers, Sharon A. Vantyghem, Alan B. Tuck, Alison L. Allan
Publikováno v:
Cytometry. Part A : the journal of the International Society for Analytical Cytology. 65(1)
Background Circulating tumor cells (CTCs) in the peripheral blood of breast cancer patients may be an important indicator of metastatic disease and poor prognosis. However, the use of experimental models is required to fully elucidate the functional
Autor:
Kara A, Furger, Alison L, Allan, Sylvia M, Wilson, Charulata, Hota, Sharon A, Vantyghem, Carl O, Postenka, Waleed, Al-Katib, Ann F, Chambers, Alan B, Tuck
Publikováno v:
Molecular cancer research : MCR. 1(11)
Osteopontin (OPN) is a secreted phosphoprotein that has been associated with malignancy of breast and other cancers. OPN binds to several cell surface integrins including alpha(v)beta(3), alpha(v)beta(5), and alpha(v)beta(1). Although the relative co
Publikováno v:
Breast Cancer Research : BCR
Recent technological advances have led to an increasing ability to detect isolated tumour cells and groups of tumour cells in patients' blood, lymph nodes or bone marrow. However, the clinical significance of these cells is unclear. Should they be co